1. [CASE 1 — QUESTION 1]
A 55-year-old woman with breast cancer is scheduled to begin a highly emetogenic chemotherapy regimen (an anthracycline-cyclophosphamide combination). She has no significant cardiac history, a normal baseline ECG, and is not on any QTc-prolonging medications. The oncology team is designing prophylaxis to prevent both acute and delayed chemotherapy-induced nausea and vomiting. For the acute phase (within the first 24 hours), which prophylactic regimen is most consistent with guideline-concordant care for highly emetogenic chemotherapy?
A) A motilin receptor agonist alone
B) A three-drug combination of a 5-HT3 receptor antagonist plus an NK1 receptor antagonist plus dexamethasone
C) A scopolamine patch alone
D) Low-dose haloperidol as monotherapy
E) A single 5-HT3 receptor antagonist as monotherapy
ANSWER: B
Rationale:
Guideline-concordant prophylaxis for highly emetogenic chemotherapy consists of three-drug combination therapy: a 5-HT3 receptor antagonist plus an NK1 receptor antagonist plus dexamethasone on day 1, which covers the acute phase and sets up delayed-phase coverage.
Option A: Option A is incorrect because a motilin agonist is a prokinetic for gastroparesis, not an antiemetic regimen for chemotherapy.
Option C: Option C is incorrect because scopolamine targets the vestibular pathway of motion sickness, not the chemoreceptor trigger zone and vagal pathways driving chemotherapy nausea.
Option D: Option D is incorrect because low-dose haloperidol is used for opioid-induced or palliative nausea, not as guideline first-line prophylaxis for highly emetogenic chemotherapy.
Option E: Option E is incorrect because single-agent 5-HT3 antagonist therapy does not adequately cover the delayed phase and is insufficient for highly emetogenic regimens.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The team selects aprepitant as the NK1 receptor antagonist and plans to include dexamethasone in the regimen. A pharmacist reviewing the orders recommends adjusting the dexamethasone dose. What is the correct adjustment and its rationale?
A) Increase the dexamethasone dose because aprepitant accelerates its clearance
B) Make no change because aprepitant does not interact with dexamethasone
C) Discontinue dexamethasone because it has no role alongside an NK1 antagonist
D) Reduce the dexamethasone dose (to approximately 8 mg) because aprepitant is a moderate CYP3A4 inhibitor that raises dexamethasone plasma concentrations
E) Replace dexamethasone with a non-corticosteroid because the combination is contraindicated
ANSWER: D
Rationale:
Aprepitant is a moderate CYP3A4 inhibitor, and because dexamethasone is a CYP3A4 substrate, co-administration raises dexamethasone exposure; the dexamethasone dose is therefore reduced (to approximately 8 mg) to account for the increased concentration.
Option A: Option A is incorrect because aprepitant inhibits rather than accelerates dexamethasone metabolism, so levels rise and the dose is decreased.
Option B: Option B is incorrect because a clinically meaningful CYP3A4-mediated interaction does exist.
Option C: Option C is incorrect because dexamethasone remains a valuable adjunct that improves complete response rates and should be continued at the adjusted dose.
Option E: Option E is incorrect because the combination is standard and well managed by dose reduction, not contraindicated.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. She tolerates the day-1 regimen well with no nausea on the day of chemotherapy, but on days 2 and 3 she develops significant nausea and vomiting. What does this delayed pattern most likely reflect?
A) The delayed phase of chemotherapy-induced nausea and vomiting, mediated principally by substance P acting at NK1 receptors
B) A new motion-sickness syndrome mediated by the vestibular pathway
C) Acute-phase serotonin release that was simply undertreated on day 1
D) Gastroparesis caused by the chemotherapy agents
E) An anticipatory nausea response driven entirely by cortical input
ANSWER: A
Rationale:
Nausea and vomiting peaking on days 2 to 3 is characteristic of the delayed phase of chemotherapy-induced nausea and vomiting, which is mediated principally by substance P acting at NK1 receptors.
Option B: Option B is incorrect because the pattern reflects delayed chemotherapy emesis, not a vestibular motion-sickness syndrome.
Option C: Option C is incorrect because the acute serotonin-mediated phase occurs within the first 24 hours, whereas the substance P/NK1-mediated delayed phase drives symptoms on days 2 to 5.
Option D: Option D is incorrect because the timing and context indicate delayed CINV rather than chemotherapy-induced gastroparesis.
Option E: Option E is incorrect because anticipatory nausea typically precedes chemotherapy and is a learned cortical response, not the post-treatment delayed emesis described here.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. For her next cycle, the team wants to optimize the 5-HT3 receptor antagonist choice to better cover the delayed phase. Which agent and rationale are most appropriate?
A) Switch to high-dose intravenous ondansetron above 32 mg for longer duration
B) Use two first-generation 5-HT3 antagonists together to extend coverage
C) Use a motilin receptor agonist in place of the 5-HT3 antagonist
D) Discontinue the 5-HT3 antagonist entirely and rely on dexamethasone alone
E) Use palonosetron, whose long half-life and high receptor binding affinity provide superior delayed-phase coverage compared with ondansetron, with minimal QTc risk
ANSWER: E
Rationale:
Palonosetron has a long half-life (approximately 40 hours) and high receptor binding affinity, giving it superior delayed-CINV coverage compared with ondansetron, along with minimal hERG affinity and therefore little clinically significant QTc prolongation.
Option A: Option A is incorrect because the FDA advises against single intravenous ondansetron doses greater than 32 mg owing to dose-dependent QTc prolongation, and a higher dose would not match palonosetron's durable coverage.
Option B: Option B is incorrect because combining two first-generation agents adds no meaningful pharmacokinetic advantage and does not improve delayed coverage.
Option C: Option C is incorrect because motilin agonists are prokinetics, not antiemetics for chemotherapy nausea.
Option D: Option D is incorrect because dexamethasone alone would leave the serotonin-mediated component undertreated, and the goal is to optimize rather than remove the 5-HT3 antagonist.
5. [CASE 2 — QUESTION 1]
A 48-year-old man with a 15-year history of poorly controlled type 1 diabetes presents with chronic nausea, early satiety, postprandial fullness, and occasional vomiting of undigested food. Upper endoscopy shows no mechanical obstruction. The clinician suspects diabetic gastroparesis. Which finding would establish the diagnosis?
A) An elevated fasting serum gastrin level
B) Accelerated gastric emptying on a radiolabeled meal study
C) Gastric emptying scintigraphy showing retention of more than 10% of a standardized radiolabeled solid meal at 4 hours, with mechanical obstruction excluded
D) A positive urea breath test for Helicobacter pylori
E) An elevated serum lipase confirming pancreatitis
ANSWER: C
Rationale:
Gastroparesis is diagnosed by gastric emptying scintigraphy demonstrating retention of greater than 10% of a standardized radiolabeled solid meal at 4 hours after ingestion, with mechanical obstruction excluded by endoscopy or imaging.
Option A: Option A is incorrect because serum gastrin is not a diagnostic criterion for gastroparesis.
Option B: Option B states the opposite of the defining abnormality: emptying is delayed, not accelerated.
Option D: Option D is incorrect because Helicobacter pylori testing addresses peptic disease, not the motility defect of gastroparesis.
Option E: Option E is incorrect because an elevated lipase points to pancreatitis, which is a different diagnosis from gastroparesis.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. His diabetic gastroparesis is confirmed. The clinician plans to start first-line pharmacological therapy. Which agent is appropriate, and what important safety constraint governs its use?
A) Domperidone, which is the FDA-approved first-line agent for gastroparesis in the United States, with no duration limit
B) Metoclopramide, the only FDA-approved drug for gastroparesis in the United States, used at the lowest effective dose for no longer than 12 weeks because of the black-box risk of tardive dyskinesia
C) Prucalopride, approved specifically for diabetic gastroparesis, used indefinitely
D) Ondansetron, used as a first-line prokinetic for gastroparesis
E) Erythromycin, the FDA-approved first-line agent for chronic long-term gastroparesis management
ANSWER: B
Rationale:
Metoclopramide is the only FDA-approved drug for gastroparesis in the United States and is first-line, but it carries a black-box warning limiting use to no longer than 12 weeks because of the risk of tardive dyskinesia, so it should be used at the lowest effective dose for the shortest necessary period.
Option A: Option A is incorrect because domperidone is not approved for sale in the United States and is available only through expanded-access pathways.
Option C: Option C is incorrect because prucalopride is approved for chronic idiopathic constipation, not gastroparesis.
Option D: Option D is incorrect because ondansetron is an antiemetic without prokinetic activity.
Option E: Option E is incorrect because erythromycin is used off-label and is limited by tachyphylaxis, making it suitable for acute exacerbations rather than approved first-line chronic management.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. He is stable on metoclopramide for several weeks, then presents with an abrupt worsening of nausea and vomiting during an episode of markedly elevated blood glucose (glucose 410 mg/dL). What is the most appropriate understanding of this deterioration and the key management priority?
A) Acute hyperglycemia itself inhibits gastric motility and can precipitate a gastroparetic crisis, so correcting the hyperglycemia is a central management priority alongside hydration and antiemetics
B) Acute hyperglycemia accelerates gastric emptying, so the worsening must be from metoclopramide toxicity
C) The hyperglycemia is irrelevant because glucose has no effect on gastric motility
D) The symptoms indicate that metoclopramide has caused tardive dyskinesia
E) The presentation indicates a new mechanical obstruction requiring urgent surgery
ANSWER: A
Rationale:
Acute hyperglycemia independently inhibits gastric motility and can precipitate an acute gastroparetic crisis, so correcting the blood glucose is a central management priority along with hydration and antiemetic therapy; tight glycemic control also slows progression of the underlying autonomic neuropathy.
Option B: Option B is incorrect because acute hyperglycemia inhibits rather than accelerates emptying.
Option C: Option C is incorrect because hyperglycemia has a well-established inhibitory effect on gastric motility.
Option D: Option D is incorrect because tardive dyskinesia is a movement disorder, not an acute vomiting crisis.
Option E: Option E is incorrect because gastroparesis is by definition delayed emptying in the absence of mechanical obstruction, and the picture reflects a hyperglycemia-driven exacerbation rather than a new obstruction.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. Over the following months, despite optimized glycemic control, dietary modification (small, frequent low-fat low-fiber meals), and trials of metoclopramide and intermittent erythromycin, he continues to have severe, refractory nausea and vomiting. What is the most appropriate next step?
A) Begin indefinite high-dose metoclopramide regardless of the 12-week limit
B) Start long-term continuous erythromycin, expecting sustained benefit
C) Initiate central venous parenteral nutrition as the first escalation
D) Refer for evaluation for gastric electrical stimulation, an FDA-approved device therapy for medically refractory nausea and vomiting in diabetic and idiopathic gastroparesis
E) Discontinue all therapy, as no further options remain
ANSWER: D
Rationale:
Gastric electrical stimulation with an implanted neurostimulator is an FDA-approved device therapy for medically refractory nausea and vomiting in diabetic and idiopathic gastroparesis; it primarily improves symptom burden through vagal afferent modulation. Referral for evaluation is therefore the appropriate next step in this refractory patient.
Option A: Option A is incorrect because the 12-week black-box limit and dose escalation in the face of refractory disease are inappropriate and unsafe.
Option B: Option B is incorrect because erythromycin's prokinetic effect wanes with continuous use due to tachyphylaxis, so it is not suitable for long-term management.
Option C: Option C is incorrect because parenteral nutrition is reserved as a last resort when enteral (nasojejunal) feeding is not feasible, not as the first escalation.
Option E: Option E is incorrect because device therapy and continued supportive measures remain available, so stopping all therapy is unjustified.
9. [CASE 3 — QUESTION 1]
A 67-year-old woman is in the post-anesthesia care unit after elective orthopedic surgery and develops postoperative nausea and vomiting. Her preoperative ECG showed a borderline-prolonged QTc, and she takes a QTc-prolonging antiarrhythmic at home. The anesthesiologist wants effective antiemetic control while minimizing additional arrhythmia risk. Which initial approach is most appropriate?
A) High-dose droperidol, since its black box warning is irrelevant in adults
B) A large single intravenous ondansetron dose well above 32 mg for rapid control
C) Withhold all antiemetics permanently because nothing is safe in this patient
D) High-dose promethazine, since phenothiazines do not affect the QTc
E) Favor a low-arrhythmia-risk agent such as dexamethasone and, if a second agent is needed, the lowest effective dose of ondansetron with QTc attention, while avoiding droperidol given its black box warning for QTc prolongation and fatal arrhythmias
ANSWER: E
Rationale:
In a patient with a borderline-prolonged QTc already on a QTc-prolonging antiarrhythmic, the safest approach is to favor a low-arrhythmia-risk antiemetic such as dexamethasone and, if a second agent is needed, use the lowest effective dose of ondansetron with QTc attention, while avoiding droperidol, which carries a black box warning for QTc prolongation and fatal arrhythmias.
Option A: Option A is incorrect because the droperidol QTc black box warning applies to adults and high-dose use would be hazardous.
Option B: Option B is incorrect because the FDA advises against single intravenous ondansetron doses greater than 32 mg owing to dose-dependent QTc prolongation.
Option C: Option C is incorrect because effective lower-risk options exist, so withholding all antiemetics is unjustified.
Option D: Option D is incorrect because phenothiazines such as promethazine do prolong the QTc, so high-dose use would add to the risk.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. A trainee asks why ondansetron, if used, must be dose-limited in this patient. What is the correct explanation of ondansetron's cardiac liability and the relevant dosing limit?
A) Ondansetron causes extrapyramidal symptoms, so the dose is limited to prevent dystonia
B) Ondansetron prolongs the PR interval through calcium channel blockade, so the dose is capped
C) Ondansetron prolongs the QTc interval through cardiac hERG potassium channel blockade in a dose-dependent manner, and the FDA recommends against single intravenous doses greater than 32 mg
D) Ondansetron causes profound hypotension, so the dose is limited to protect blood pressure
E) Ondansetron is hepatotoxic at high doses, which is the basis for the dose limit
ANSWER: C
Rationale:
Ondansetron prolongs the QTc interval through cardiac hERG (human ether-a-go-go-related gene) potassium channel blockade in a dose-dependent fashion, and the FDA recommends against single intravenous doses greater than 32 mg; the concern is heightened with pre-existing QTc prolongation, electrolyte abnormalities, or concurrent QTc-prolonging drugs.
Option A: Option A is incorrect because ondansetron lacks dopamine D2 activity and does not cause extrapyramidal symptoms.
Option B: Option B is incorrect because the relevant effect is QTc prolongation via hERG blockade, not PR prolongation from calcium channel blockade.
Option D: Option D is incorrect because dose-limiting hypotension is not the basis for the ondansetron ceiling.
Option E: Option E is incorrect because the dose limit reflects QTc prolongation risk, not hepatotoxicity.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. Laboratory studies now reveal hypokalemia and hypomagnesemia from her perioperative course. How does this finding modify the antiemetic plan?
A) The electrolyte abnormalities shorten the QTc and therefore make any antiemetic safer
B) Hypokalemia and hypomagnesemia independently prolong the QTc and compound the torsades de pointes risk from a QTc-prolonging antiemetic, so the electrolytes should be corrected and the lowest effective antiemetic dose used
C) The electrolyte abnormalities are irrelevant to QTc and require no action before dosing
D) The low magnesium worsens extrapyramidal risk from ondansetron and should be corrected for that reason
E) The findings indicate that droperidol is now the safest choice
ANSWER: B
Rationale:
Hypokalemia and hypomagnesemia independently prolong the QTc interval, so in a patient already at risk they compound the danger of torsades de pointes when a QTc-prolonging antiemetic is given; the electrolytes should be corrected and the lowest effective antiemetic dose used.
Option A: Option A is incorrect because these electrolyte abnormalities prolong rather than shorten the QTc.
Option C: Option C is incorrect because the abnormalities are directly relevant to QTc risk and must be addressed.
Option D: Option D is incorrect because ondansetron does not cause extrapyramidal symptoms; the concern is additive QTc prolongation.
Option E: Option E is incorrect because droperidol carries a black box warning for QTc prolongation and fatal arrhythmias and is not made safer by these electrolyte derangements.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. A colleague suggests droperidol, recalling its historical popularity for postoperative nausea. Why did droperidol use decline substantially, and what is the underlying concern?
A) The FDA issued a black box warning in 2001 for QTc prolongation and the risk of fatal ventricular arrhythmias, which markedly reduced its use
B) Droperidol was withdrawn entirely from the market for hepatotoxicity
C) Droperidol caused widespread tardive dyskinesia after single doses
D) Droperidol was associated with fatal respiratory depression in adults
E) Droperidol lost favor because it was ineffective for postoperative nausea
ANSWER: A
Rationale:
Droperidol use declined substantially after the FDA issued a black box warning in 2001 for QTc prolongation and the risk of fatal ventricular arrhythmias; it retains only a limited low-dose role where QTc risk is acceptable.
Option B: Option B is incorrect because droperidol was not withdrawn for hepatotoxicity; it remains available but is used cautiously.
Option C: Option C is incorrect because tardive dyskinesia from prolonged dopamine blockade is the basis for the metoclopramide warning, not a single-dose droperidol effect.
Option D: Option D is incorrect because fatal respiratory depression in young children is the promethazine warning, not a droperidol concern in adults.
Option E: Option E is incorrect because droperidol is an effective antiemetic; its decline was driven by the QTc and arrhythmia concern, not lack of efficacy.
13. [CASE 4 — QUESTION 1]
A 22-year-old woman is treated in the emergency department with intravenous metoclopramide for severe nausea. Within an hour she develops sustained involuntary neck contraction pulling her head to one side and a forced upward gaze she cannot voluntarily suppress. What is the most likely cause of these findings?
A) An anaphylactic reaction to metoclopramide
B) Tardive dyskinesia developing after a single intravenous dose
C) A primary seizure disorder unmasked by the medication
D) An acute dystonic reaction from dopamine D2 receptor blockade in the nigrostriatal pathway, a recognized early extrapyramidal effect of metoclopramide that is more common in young patients
E) A hypertensive crisis triggered by metoclopramide
ANSWER: D
Rationale:
The combination of torticollis and oculogyric crisis shortly after intravenous metoclopramide is a classic acute dystonic reaction, an extrapyramidal effect of dopamine D2 receptor blockade in the nigrostriatal pathway; acute dystonia is more common in young patients and after parenteral administration.
Option A: Option A is incorrect because anaphylaxis presents with urticaria, angioedema, bronchospasm, and hypotension rather than focal sustained muscle contractions.
Option B: Option B is incorrect because tardive dyskinesia develops after prolonged use and consists of repetitive choreoathetoid orofacial movements, not an acute single-dose dystonic reaction.
Option C: Option C is incorrect because the stereotyped dystonic posturing temporally linked to a D2 antagonist is characteristic of drug-induced dystonia, not a primary seizure.
Option E: Option E is incorrect because metoclopramide does not characteristically cause a hypertensive crisis, and the findings are dystonic rather than hypertensive.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. She is later placed on chronic oral metoclopramide for documented gastroparesis. After several weeks she reports milky breast discharge and missed menstrual periods; a pregnancy test is negative. What is the mechanism of these new symptoms?
A) Direct agonism at pituitary prolactin receptors by metoclopramide
B) Estrogen receptor agonism in breast and pituitary tissue
C) Dopamine D2 receptor blockade in the tuberoinfundibular pathway, which removes dopamine's tonic inhibition of pituitary lactotrophs and raises prolactin, producing galactorrhea and amenorrhea
D) Reduced hepatic clearance of prolactin caused by metoclopramide
E) Stimulation of hypothalamic thyrotropin-releasing hormone by metoclopramide
ANSWER: C
Rationale:
Metoclopramide blocks dopamine D2 receptors in the tuberoinfundibular pathway, removing dopamine's tonic inhibition of pituitary lactotrophs and increasing prolactin secretion; the resulting hyperprolactinemia causes galactorrhea, amenorrhea, and sexual dysfunction.
Option A: Option A is incorrect because metoclopramide does not directly agonize prolactin receptors; it disinhibits prolactin release upstream.
Option B: Option B is incorrect because metoclopramide has no estrogenic activity.
Option D: Option D is incorrect because the mechanism is increased secretion from loss of dopaminergic inhibition, not reduced hepatic clearance.
Option E: Option E is incorrect because the cause is loss of dopaminergic inhibition of lactotrophs rather than thyrotropin-releasing hormone stimulation.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient's family history: her father has Parkinson disease and also has gastroparesis requiring a prokinetic. A clinician asks which prokinetic consideration applies to him. What is the correct guidance for the father?
A) Metoclopramide is preferred in Parkinson disease because central D2 blockade improves tremor
B) Metoclopramide should be avoided because it crosses the blood-brain barrier and blocks central D2 receptors, worsening the dopamine-deficient motor state of Parkinson disease; where a prokinetic is needed, domperidone is preferred because it is largely excluded from the CNS and spares central dopamine receptors
C) Ondansetron is the preferred prokinetic for Parkinson patients
D) Domperidone must be avoided in Parkinson disease because it readily enters the CNS and worsens parkinsonism
E) No prokinetic can ever be used in Parkinson disease
ANSWER: B
Rationale:
Metoclopramide crosses the blood-brain barrier and blocks central dopamine D2 receptors, worsening the already dopamine-deficient motor state of Parkinson disease, so it should be avoided; where a prokinetic is needed, domperidone is preferred because it is a P-glycoprotein substrate largely excluded from the CNS and therefore spares central dopamine receptors.
Option A: Option A is incorrect because central D2 blockade worsens, not improves, parkinsonian motor symptoms.
Option C: Option C is incorrect because ondansetron is an antiemetic without prokinetic activity.
Option D: Option D is incorrect because domperidone does not readily enter the CNS, which is precisely why it is favored in parkinsonian patients.
Option E: Option E is incorrect because a CNS-sparing prokinetic such as domperidone can be used, so the categorical prohibition is wrong.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. She asks why metoclopramide carries a strict 12-week limit. What is the correct explanation of the mechanism and clinical consequence behind this limit?
A) Acute dose-dependent QTc prolongation that resolves immediately on discontinuation
B) Reversible hyperprolactinemia that fully normalizes regardless of continued use
C) Cumulative hepatocyte injury producing reversible transaminase elevation
D) Depletion of striatal dopamine stores that recovers immediately when the drug is stopped
E) Striatal dopamine D2 receptor upregulation and sensitization after prolonged blockade, producing tardive dyskinesia that is often irreversible even after the drug is discontinued
ANSWER: E
Rationale:
Tardive dyskinesia from metoclopramide results from dopamine D2 receptor upregulation and sensitization in the striatum after prolonged blockade; it consists of repetitive involuntary orofacial and limb movements and is often irreversible even after the drug is stopped, which is the basis for the FDA black-box 12-week limit.
Option A: Option A is incorrect because QTc prolongation is not the basis for this duration limit.
Option B: Option B is incorrect because, although hyperprolactinemia occurs, the limit is grounded in the often-irreversible movement disorder, not a self-normalizing prolactin effect.
Option C: Option C is incorrect because hepatocyte injury is not the mechanism behind the warning.
Option D: Option D is incorrect because the mechanism is receptor upregulation from blockade, not depletion of dopamine stores.
17. [CASE 5 — QUESTION 1]
A 70-year-old man plans an ocean cruise and is prone to severe motion sickness. He asks for the most effective single agent to prevent it. Which drug and mechanism is the best initial recommendation, before considering his individual risk factors?
A) Scopolamine, a competitive muscarinic M1 receptor antagonist that acts on vestibular nucleus neurons to interrupt the vestibular afferent pathway to the vomiting center, making it the most effective single agent for motion sickness
B) Ondansetron, a 5-HT3 antagonist that blocks the vestibular pathway
C) Aprepitant, an NK1 antagonist that prevents motion sickness
D) Metoclopramide, a D2 antagonist that is first-line for motion sickness
E) Erythromycin, a motilin agonist used to prevent motion sickness
ANSWER: A
Rationale:
Scopolamine is a competitive muscarinic M1 receptor antagonist that acts on vestibular nucleus neurons to interrupt the vestibular afferent pathway to the vomiting center, making it the most effective single agent for motion sickness; the transdermal patch provides sustained blockade.
Option B: Option B is incorrect because ondansetron targets the peripheral serotonin/vagal pathway of acute chemotherapy nausea, not the vestibular pathway.
Option C: Option C is incorrect because NK1 antagonists target the delayed phase of chemotherapy nausea, not motion sickness.
Option D: Option D is incorrect because metoclopramide acts at the chemoreceptor trigger zone and on gut motility, not as a first-line motion-sickness agent.
Option E: Option E is incorrect because erythromycin is a prokinetic for gastroparesis and has no role in motion sickness.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. His history includes angle-closure glaucoma and benign prostatic hyperplasia. Given these comorbidities and his age, what is the most important consideration before recommending a scopolamine patch?
A) Scopolamine is ideal here because its anticholinergic action improves both glaucoma and prostatic symptoms
B) The comorbidities are irrelevant because scopolamine has no anticholinergic effects
C) Scopolamine should be avoided only because it prolongs the QTc in elderly patients
D) Scopolamine's antimuscarinic action can precipitate acute angle-closure glaucoma, worsen urinary retention from benign prostatic hyperplasia, and cause confusion in elderly patients, so it should be used with great caution or avoided and an alternative considered
E) Scopolamine is safe in angle-closure glaucoma but hazardous in open-angle glaucoma
ANSWER: D
Rationale:
Scopolamine is a muscarinic antagonist whose anticholinergic effects can precipitate acute angle-closure glaucoma, worsen urinary retention from benign prostatic hyperplasia, and cause confusion in elderly patients, so it should be used with great caution or avoided in this man, with an alternative considered.
Option A: Option A is incorrect because anticholinergic activity worsens, rather than improves, angle-closure glaucoma and prostatic outflow obstruction.
Option B: Option B is incorrect because scopolamine has prominent anticholinergic effects directly relevant to these comorbidities.
Option C: Option C is incorrect because the principal concern is anticholinergic toxicity, not QTc prolongation.
Option E: Option E is incorrect because anticholinergic agents are specifically hazardous in angle-closure glaucoma, the opposite of what this option states.
19. [CASE 5 — QUESTION 3]
Continuing with the same scenario: the patient's daughter asks whether her 18-month-old child could use promethazine for vomiting during travel. What is the correct guidance regarding promethazine in this age group?
A) Promethazine is the preferred pediatric antiemetic because of its strong safety record in infants
B) Promethazine is safe at any age provided the dose is weight-based
C) Promethazine carries an FDA black box warning against use in children under age 2 because it can cause fatal respiratory depression, so it should not be given to an 18-month-old
D) Promethazine has no antihistamine or anticholinergic activity, so it poses no central risk in children
E) Promethazine is contraindicated only in children over age 2
ANSWER: C
Rationale:
Promethazine, a phenothiazine with significant histamine H1 antihistamine and anticholinergic activity, carries an FDA black box warning against use in children under age 2 because it can cause fatal respiratory depression; it should therefore not be given to an 18-month-old.
Option A: Option A is incorrect because promethazine is contraindicated, not preferred, in this age group.
Option B: Option B is incorrect because weight-based dosing does not eliminate the risk of fatal respiratory depression in young children.
Option D: Option D is incorrect because promethazine does have prominent antihistamine and anticholinergic activity and poses central risks.
Option E: Option E reverses the warning: the contraindication applies to children under age 2, not those over age 2.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. If a scopolamine patch is ultimately used by an appropriate adult, what specific handling instruction is important, and why?
A) The patch should be cut in half to reduce the dose, which is safe and recommended
B) Hands must be washed thoroughly after handling the patch, because inadvertent transfer of drug to the eye can precipitate acute angle-closure glaucoma in susceptible individuals
C) The patch should be applied directly over the eye for fastest absorption
D) The patch may be shared between travelers to reduce waste
E) No handling precautions are necessary because systemic absorption is negligible
ANSWER: B
Rationale:
After handling a scopolamine patch, hands must be washed thoroughly because inadvertent transfer of drug to the eye can cause unilateral mydriasis and can precipitate acute angle-closure glaucoma in susceptible individuals.
Option A: Option A is incorrect because cutting the patch disrupts its controlled-release delivery and is not a recommended way to reduce the dose.
Option C: Option C is incorrect because the patch is applied behind the ear, never on or near the eye.
Option D: Option D is incorrect because patches are single-patient devices and should not be shared.
Option E: Option E is incorrect because scopolamine is systemically absorbed and ocular exposure from the hands is a real hazard, so handling precautions are necessary.
21. [CASE 6 — QUESTION 1]
A 40-year-old man undergoing chemotherapy has refractory nausea despite a standard three-drug antiemetic regimen and also has significant anorexia and weight loss. The team considers dronabinol. Which description best captures its pharmacology and appropriate role here?
A) A 5-HT3 antagonist that should simply replace ondansetron in the regimen
B) A dopamine D2 antagonist used first-line for postoperative nausea
C) A motilin receptor agonist used primarily for gastroparesis
D) An NK1 antagonist that is the preferred first-line agent for delayed CINV
E) A synthetic delta-9-tetrahydrocannabinol that is a CB1 cannabinoid receptor partial agonist with antiemetic and orexigenic effects, FDA-approved for refractory chemotherapy-induced nausea and for AIDS-related anorexia and a Schedule III controlled substance, making it a reasonable rescue option in this patient with refractory nausea and concurrent anorexia
ANSWER: E
Rationale:
Dronabinol is a synthetic delta-9-tetrahydrocannabinol that acts as a partial agonist at CB1 cannabinoid receptors, producing antiemetic and orexigenic (appetite-stimulating) effects; it is FDA-approved for chemotherapy-induced nausea refractory to conventional antiemetics and for anorexia in AIDS, and it is a Schedule III controlled substance, making it a reasonable rescue option in a patient with refractory nausea and concurrent anorexia.
Option A: Option A is incorrect because dronabinol acts at CB1 receptors, not 5-HT3 receptors.
Option B: Option B is incorrect because it is not a dopamine D2 antagonist or a first-line postoperative agent.
Option C: Option C is incorrect because it is not a motilin agonist or a gastroparesis prokinetic.
Option D: Option D is incorrect because dronabinol is not an NK1 antagonist and is a rescue agent rather than first-line therapy for delayed CINV.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. He also develops markedly delayed gastric emptying during his treatment course, and the team considers a prokinetic. They ask about low-dose erythromycin. Which statement best describes its mechanism and the limitation that governs its use?
A) It blocks dopamine D2 receptors centrally, providing durable long-term prokinetic benefit
B) It is a 5-HT3 antagonist whose prokinetic effect is sustained indefinitely
C) It is a motilin receptor agonist that produces potent antral contractions and is excellent for acute use, but tachyphylaxis from motilin receptor downregulation within days to weeks limits its long-term value
D) It is a muscarinic antagonist that accelerates gastric emptying without tolerance
E) It is a selective 5-HT4 agonist with no risk of diminishing effect over time
ANSWER: C
Rationale:
Low-dose erythromycin is a motilin receptor agonist that produces potent antral contractions, making it excellent for acute use such as a gastroparetic crisis; however, tachyphylaxis from motilin receptor downregulation within days to weeks of continuous administration limits its long-term value.
Option A: Option A is incorrect because erythromycin acts at motilin receptors, not central D2 receptors, and its benefit is not durable over the long term.
Option B: Option B is incorrect because erythromycin is not a 5-HT3 antagonist and its prokinetic effect wanes with continuous use.
Option D: Option D is incorrect because erythromycin is not a muscarinic antagonist and does develop tolerance.
Option E: Option E is incorrect because erythromycin is not a 5-HT4 agonist (that describes prucalopride) and its effect does diminish over time.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. He is also on chronic warfarin for a prior venous thromboembolism. His antiemetic regimen includes aprepitant. Over the following week his INR drifts below the therapeutic range with no change in warfarin dose or diet. What is the explanation and the appropriate action?
A) Aprepitant induces CYP2C9, accelerating warfarin metabolism and lowering the INR, so the INR should be monitored closely and the warfarin dose adjusted as needed
B) Aprepitant inhibits CYP2C9, raising the INR, so the warfarin dose should be reduced
C) Aprepitant displaces warfarin from plasma proteins, raising the INR
D) Aprepitant directly antagonizes vitamin K, raising the INR
E) Aprepitant has no interaction with warfarin, so the change is a laboratory artifact
ANSWER: A
Rationale:
Aprepitant induces CYP2C9, the enzyme largely responsible for metabolizing the active S-enantiomer of warfarin; this accelerates warfarin clearance and lowers the INR, so the INR should be monitored closely during and after the aprepitant course and the warfarin dose adjusted as needed.
Option B: Option B is incorrect because aprepitant induces rather than inhibits CYP2C9, so the INR falls rather than rises.
Option C: Option C is incorrect because the interaction is enzyme induction, not protein-binding displacement, and the observed change is a falling INR.
Option D: Option D is incorrect because aprepitant does not antagonize vitamin K, and the effect is a decrease in the INR.
Option E: Option E is incorrect because a recognized CYP2C9-mediated interaction explains the falling INR, so it is not a laboratory artifact.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. During recovery he develops chronic constipation, and a 5-HT4 agonist is considered. The team recalls that an earlier 5-HT4 agonist, cisapride, was withdrawn for safety reasons. Which statement correctly distinguishes prucalopride from cisapride and explains why prucalopride is the safer option?
A) Prucalopride acts on motilin receptors rather than 5-HT4 receptors, avoiding cardiac effects
B) Prucalopride blocks rather than activates 5-HT4 receptors, eliminating proarrhythmic signaling
C) Prucalopride and cisapride have identical cardiac profiles, and cisapride was withdrawn for hepatotoxicity
D) Prucalopride is a selective, high-affinity 5-HT4 agonist with no significant cardiac hERG channel affinity and does not prolong the QTc, whereas non-selective cisapride blocked hERG channels and caused fatal ventricular arrhythmias
E) Prucalopride is rapidly cleared by the kidney before reaching cardiac tissue, which is the basis for its safety
ANSWER: D
Rationale:
Prucalopride is a selective, high-affinity 5-HT4 receptor agonist with no significant affinity for cardiac hERG channels, so it does not prolong the QTc interval; cisapride, a non-selective 5-HT4 agonist, blocked hERG channels and caused fatal ventricular arrhythmias, leading to its withdrawal, and prucalopride was designed to retain prokinetic 5-HT4 activity without that cardiac liability.
Option A: Option A is incorrect because prucalopride acts at 5-HT4 receptors, not motilin receptors.
Option B: Option B is incorrect because prucalopride is a 5-HT4 agonist, not an antagonist, and agonism produces its prokinetic colonic effect.
Option C: Option C is incorrect because the two differ markedly in cardiac safety and cisapride was withdrawn for arrhythmia, not hepatotoxicity.
Option E: Option E is incorrect because the safety advantage stems from receptor selectivity and the absence of hERG affinity, not renal clearance.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.